Jonathan Aschoff

Stock Analyst at Roth Capital

(0.49)
# 4,139
Out of 5,042 analysts
38
Total ratings
25%
Success rate
-35.72%
Average return

Stocks Rated by Jonathan Aschoff

GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.68
Upside: +1,507.01%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19$21
Current: $10.61
Upside: +97.93%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100$5,920
Current: $1.52
Upside: +389,373.68%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15$18
Current: $1.57
Upside: +1,046.50%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $3.25
Upside: +21,869.23%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.57
Upside: +3,430.45%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.49
Upside: +8,130.45%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600$840
Current: $4.00
Upside: +20,900.00%
Mind Medicine (MindMed)
Mar 7, 2024
Maintains: Buy
Price Target: $25$36
Current: $12.38
Upside: +190.79%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750$18,000
Current: $6.70
Upside: +268,556.72%
Reiterates: Buy
Price Target: $30
Current: $7.39
Upside: +305.95%
Reiterates: Buy
Price Target: $200
Current: $8.34
Upside: +2,298.08%
Reiterates: Buy
Price Target: $14
Current: $3.61
Upside: +287.81%
Maintains: Buy
Price Target: $7,200$21,600
Current: $1.27
Upside: +1,700,687.40%
Reinstates: Buy
Price Target: $8
Current: $1.61
Upside: +396.89%
Initiates: Buy
Price Target: $100
Current: $4.88
Upside: +1,949.18%
Initiates: Buy
Price Target: $400
Current: $1.10
Upside: +36,263.64%
Initiates: Buy
Price Target: $38
Current: $10.75
Upside: +253.49%
Downgrades: Sell
Price Target: $96
Current: $2.33
Upside: +4,020.17%
Initiates: Buy
Price Target: $13
Current: $1.90
Upside: +584.21%